Dermira Inc (DERM) Given Average Recommendation of “Hold” by Brokerages
Shares of Dermira Inc (NASDAQ:DERM) have been assigned an average rating of “Hold” from the eleven analysts that are currently covering the stock, Marketbeat Ratings reports. Four analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and six have issued a buy recommendation on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $43.20.
A number of analysts have issued reports on the stock. BidaskClub raised shares of Dermira from a “strong sell” rating to a “sell” rating in a report on Wednesday, August 16th. Mizuho reissued a “buy” rating and issued a $43.00 price objective (up previously from $40.00) on shares of Dermira in a report on Thursday, September 7th. Leerink Swann reissued an “outperform” rating and issued a $41.00 price objective (down previously from $47.00) on shares of Dermira in a report on Tuesday, November 7th. Guggenheim began coverage on shares of Dermira in a report on Tuesday, December 5th. They set a “buy” rating for the company. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $43.00 price target (down previously from $46.00) on shares of Dermira in a report on Tuesday, November 7th.
In related news, CEO Thomas G. Wiggans sold 9,500 shares of the company’s stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $27.51, for a total transaction of $261,345.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Eugene A. Bauer sold 7,500 shares of the company’s stock in a transaction that occurred on Wednesday, October 11th. The stock was sold at an average price of $30.04, for a total transaction of $225,300.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 28,800 shares of company stock valued at $809,425. 13.30% of the stock is currently owned by insiders.
Shares of Dermira (DERM) opened at $27.51 on Thursday. The company has a quick ratio of 4.68, a current ratio of 4.68 and a debt-to-equity ratio of 1.40. Dermira has a twelve month low of $21.35 and a twelve month high of $38.75.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.